ICOTF News Alert Ico Therapeutics (ICOTF) 0.0396 09/27/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 27, 2014 at 10:31 PM

Ico Therapeutics (ICOTF) 0.0396 $ICOTF

iCo Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 29, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"

.

iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
CNW Group - Tue Aug 19, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy.

iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity.

Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"

appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.

iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:

Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.

Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.

iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public.

iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC"

, thus providing the Company with DTC eligibility.

IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:

iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"

(TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering"

. Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units"

at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share"

and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant"

. Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant.

IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :

iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company"

(TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering"

. Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units"

at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share"

and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant"

. Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share"

for a period of five years following the closing of the Offering.

iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
PR Newswire - Tue Jan 21, 4:00PM CST
iCo Therapeutics Inc. ("iCo" or the "Company"

(TSXV: ICO) (OTCQX: ICOTF) announced today that it has undertaken an overnight marketed public offering (the "Offering"

of units (the "Units"

, comprised of common shares of the Company and common share purchase warrants (a "Warrant"

. The Offering is to be effected in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to iCo's base shelf prospectus dated July 3, 2012 and elsewhere on a private placement basis. Prior to the Offering, iCo had 67,811,230 common shares issued and outstanding. The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market.

iCo Therapeutics Begins Trading on the OTCQX Marketplace
PR Newswire - Fri Dec 20, 6:00AM CST
iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common shares will begin trading today on OTCQX International, a segment of the OTCQX marketplace in the U.S., under the symbol "ICOTF." iCo's common shares will also continue to trade on the TSX Venture Exchange under the symbol "ICO".

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...